Tue May 24, 2011 2:01pm BST TUCSON, AZ, May 24 (MARKET WIRE) -- CDEX (OTCBB: CEXI) (www.cdex-inc.com), a leading developer of chemical detection products, using patented technologies, for use in healthcare and security markets, announced today the company was one of only 15 companies invited to participate at the Amerinet Niche Technology & Supplier Diversity Fair held May 12, 2011 in Orlando, Fla.
CDEX demonstrated the improved capabilities of the new ValiMed(TM)G4 Medication Validation System to the Amerinet members and staff.
The Valimed G4 system analyzes the concentration of the drug, the diluent, the dose in sterile parenteral admixture solutions within seconds of testing. The G4 will be used as an end-of-line defense to increase patient safety which will help the hospitals pharmacies adhere to 797 compliance requirements. The G4 is also capable of providing a safety net for the ever increasing problem of narcotics diversion in the clinical and hospital environments.
The purpose of the Amerinet fair was to determine the viability for select niche healthcare technologies to be included in the portfolio of preferred products offered through their national healthcare group purchasing organization (GPO).
"We were very excited to be invited to present our cutting edge drug validation technology to the members of Amerinet. The initial reaction and feedback from attendees was very favorable and we hope to have a response regarding possible inclusion in their vendor portfolio soon," said Jeff Brumfield, chief executive officer and chairman of CDEX. "Our distribution partner HealthTrax, introduced the Valimed G4 system to the Amerinet group and secured the invite to the conference, for which we are very grateful.
Amerinet is a leading national healthcare group purchasing organization, with a membership of more than 41,000 healthcare facilities and 1,000 suppliers nationwide, access approval to the network would provide a tremendous opportunity for CDEX."
About CDEX CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed product line provides life-saving validation of high-risk medications and returned narcotics. The ID2(TM) product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched.
To learn more about CDEX please visit www.cdex-inc.com.
Safe Harbor Statement Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.
Company contact: Jeff Brumfield CDEX Inc. (520) 745-5172 investorrelations@cdex-inc.com
At reverse shows, buyers sit at designated spots, and sellers circulate to the buyers.
Thus CDEX can just go to buyers and pitch the CONCEPT... Hang BOOLSHEET on them w/o having to set up a mock-up exhibit. Maybe hand them a video or a brochure such as JAY BEE showed on the computer here. With Him and Wade telling US what a great thang is the bloody G4. Or the IMAGINARY G4...TM DIDDY or me one.
News 
Market Data 
Discover 
AI
